Für Patienten
Für Ärzte
International

Stuttgart

Zentralinstitut für Klinische Chemie und Laboratoriumsmedizin mit Laborpraxis

Wissenschaft und Lehre

Eigene/Diagnostische Studien

  • Auftragsmessungen
  • Zielwertermittlungen für Qualitätskontrollen

Analytik im Rahmen von klinischen Studien

  • ALTTO-Studie (Herr Prof. Karck, Stuttgart)
  • Ratify-Studie (Herr OA Dr. Schleicher, Stuttgart)
  • SIOP CNS GCT II-Studie (Herr Prof. Bielack, Stuttgart)
  • CWS-2007-HR-Studie (Herr Prof. Bielack, Stuttgart)
  • EWING 2008-Studie (Herr Prof. Bielack, Stuttgart)
  • RIST-rNB-2011-Therapieoptimierungsstudie (Herr Prof. Bielack, Stuttgart)
  • TTACT-Studie (Herr Prof. Illerhaus, Stuttgart)
  • SIOP PNET 5 MB-Studie (Herr Prof. Bielack, Stuttgart)
  • RESPECT ESUS-Studie (Frau OÄ Dr. Schmid, Stuttgart)
  • MATRIX-Studie (Herr Prof. Illerhaus, Stuttgart)
  • AMLSG 21-13-Studie (Herr OA Dr. Schleicher, Stuttgart)
  • FIRE-4-Studie (Herr Prof. Illerhaus, Stuttgart)
  • EuroNet-PHL-C2-Studie (Herr Prof. Bielack, Stuttgart)
  • AML-BFM 2012-Studie (Herr Prof. Bielack, Stuttgart)
  • DETECT-Studie (Herr Prof. Karck, Stuttgart)
  • Mediwound-2012-01-01-Studie (Herr OA Dr. Hannmann, Stuttgart)
  • ESOPEC-Studie (Herr Prof. Illerhaus, Stuttgart)
  • HD 21-Studie (Herr OA Dr. Hahn, Stuttgart)
  • PETRARCA/Flot6-Studie (Herr Prof. Illerhaus, Stuttgart)
  • TRIANGLE-Studie (Herr Prof. Illerhaus, Stuttgart)
  • EcNO-Studie (Herr Prof. Illerhaus, Stuttgart)
  • RIST-rPB-2015-P-Studie (Herr Prof. Bielack, Stuttgart)
  • RENAISSANCE Flot5-Studie (Frau OÄ Dr. Regincos, Stuttgart)
  • GMALL 08/2013-Studie (Herr OA Dr. Hahn, Stuttgart)
  • RAMSES/Flot7-Studie (Frau OÄ Dr. Regincos, Stuttgart)
  • Relapsed AML 2010/01-Studie (Herr Prof. Bielack, Stuttgart)
  • INTENT-Studie (Herr OA PD Dr. Bald/Frau OÄ Dr. Ruckenbrod, Stuttgart)
  • B-NHL 2013-Studie (Herr Prof. Bielack, Stuttgart)
  • LOXO-TRK-15003G-Studie (Herr Prof. Bielack, Stuttgart)
  • NEPAFOX-Studie (Herr OA Dr. Bohle, Stuttgart)
  • AIO-KHT-0115/ELDORANDO-Studie (Herr OA Dr. Hahn, Stuttgart)
  • iVAC-L-CLL01-Studie (Herr Prof. Illerhaus, Stuttgart)
  • IntReALL SR 2010-Studie (Herr Prof. Bielack, Stuttgart)
  • LCH-IV-G-2016 (Herr Prof. Bielack, Stuttgart)
  • NIVEAU-Studie DSHNHL 2015-1-Studie (Herr Prof. Illerhaus, Stuttgart)
  • AIEOP-BFM All 2017-Studie (Herr Prof. Bielack, Stuttgart)
  • HIT-HCG-2013-Studie (Herr Prof. Bielack, Stuttgart)
  • AVOID-Studie (Herr Prof. Illerhaus, Stuttgart)
  • PQR6309-02-Studie (Herr Prof. Illerhaus, Stuttgart)
  • PQR6309-05-Studie (Herr Prof. Illerhaus, Stuttgart)
  • BMS CA209-274 Nivolumumab-Studie (Herr OA Dr. Schleicher, Stuttgart)
  • E7080-G000-207 Lenvatinib-Studie (Herr Prof. Bielack, Stuttgart)
  • CTX-4430 Celtaxsys-Studie (Herr Dr. Kempa, Stuttgart)
  • RIBECCA-Studie (Herr Prof. Karck, Stuttgart)
  • BMS CA 209-647-Studie (Herr Prof. Illerhaus, Stuttgart)
  • STRONG-Studie (Herr OA Dr. Schleicher, Stuttgart)
  • Edoxaban-Studie (Herr OA Dr. Schweigmann, Stuttgart)
  • ATTICUS-Studie (Frau OÄ Dr. Schmid, Stuttgart)
  • AMPLIFY-NEOVAC-NOA 21-Studie (Frau OÄ Dr. Nadji-Ohl, Stuttgart)
  • LOXO-TRK-15003G-Studie (Herr Prof. Bielack, Stuttgart)
  • CAP-Studie (Herr Prof. Kretz, Stuttgart)
  • Entresto-Studie (Herr OA Dr. Schweigmann, Stuttgart)
  • ALTTO-Studie (Herr Prof. Karck, Stuttgart)
  • Ratify-Studie (Herr OA Dr. Schleicher, Stuttgart)
  • SIOP CNS GCT II-Studie (Herr Prof. Bielack, Stuttgart)
  • RIST-rNB-2011-Therapieoptimierungsstudie (Herr Prof. Bielack, Stuttgart)
  • SIOP PNET 5 MB-Studie (Herr Prof. Bielack, Stuttgart)
  • MATRix Studie (Herr Prof. Illerhaus, Stuttgart)
  • AMLSG 21-13-Studie (Herr Prof. Schleicher, Stuttgart)
  • EuroNet-PHL-C2-Studie (Herr Prof. Bielack, Stuttgart)
  • AML-BFM 2012-Studie (Herr Prof. Bielack, Stuttgart)
  • DETECT-Studie (Herr Prof. Karck, Stuttgart)
  • Mediwound-2012-01-01-Studie (Herr Dr. Staubach, Stuttgart)
  • ESOPEC-Studie (Herr Prof. Illerhaus, Stuttgart)
  • HD 21-Studie (Herr OA Dr. Hahn, Stuttgart)
  • PETRARCA/Flt6-Studie (Herr Prof. Illerhaus, Stuttgart)
  • TRIANGLE-Studie (Herr Prof. Illerhaus, Stuttgart)
  • RIST-rPB-2015-P-Studie (Herr Prof. Bielack, Stuttgart)
  • RENAISSANCE Flot5-Studie (Frau OÄ Dr. Regincos, Stuttgart)
  • GMALL 08/2013-Studie (Herr OA Dr. Hahn, Stuttgart)
  • Relapsed AML 2010/01-Studie (Herr Prof. Bielack, Stuttgart)
  • INTENT-Studie (Herr OA PD Dr. Bald/Frau OÄ Dr. Ruckenbrod, Stuttgart)
  • B-NHL 2013-Studie (Herr Prof. Bielack, Stuttgart)
  • LOXO-TRK-15003G-Studie (Herr Prof. Bielack, Stuttgart)
  • NEPAFOX-Studie (Herr OA Dr. Bohle, Stuttgart)
  • AIO-KHT-0115/ELDORANDO-Studie (Herr OA Dr. Hahn, Stuttgart)
  • iVAC-L-CLL01-Studie (Herr Prof. Illerhaus, Stuttgart)
  • IntReALL SR 2010-Studie (Herr Prof. Bielack, Stuttgart)
  • LCH-IV-G-2016 (Herr Prof. Bielack, Stuttgart)
  • NIVEAU-Studie DSHNHL 2015-1-Studie (Herr Prof. Illerhaus, Stuttgart)
  • AIEOP-BFM All 2017-Studie (Herr Prof. Bielack, Stuttgart)
  • HIT-HCG-2013-Studie (Herr Prof. Bielack, Stuttgart)
  • OLYMP-Studie (Herr Prof. Illerhaus, Stuttgart)
  • CARE for CAYA-Studie (Herr Prof. Bielack, Stuttgart)
  • HD7-Studie (Frau Dr. Riechel, Stuttgart)
  • LBL-2018-Studie (Herr Prof. Bielack, Stuttgart)
  • SIOP EPENDYMOMA II-Studie (Herr Prof. Bielack, Stuttgart)
  • rEECur-Studie (Herr Prof. Bielack, Stuttgart)
  • IntReALL HR 2010-Studie (Herr Prof. Bielack, Stuttgart)
  • EsPhALL2017/COGAALL1631-Studie (Herr Prof. Bielack, Stuttgart)
  • VENOBI-Studie (Herr Prof. Illerhaus, Stuttgart)
  • PHITT-Studie (Herr Prof. Bielack, Stuttgart)
  • DCVax-L-Studie (Frau OÄ Dr. Nadj-Ohl)
  • BMS CA 209-274-Studie (Herr OA Dr. Schleicher, Stuttgart)
  • BMS CA 209-647-Studie (Herr Prof. Illerhaus, Stuttgart)
  • STRONG-Studie (Herr OA Dr. Schleicher, Stuttgart)
  • ATTICUS-Studie (Herr Prof. Bäzner, Stuttgart
  • LOXO-TRK-15003G-Studie (Herr Prof. Bielack, Stuttgart)
  • Entresto-Studie (Herr OA Dr. Schweigmann, Stuttgart)
  • Landi-Ped Studie (Herr OA Dr. Schweigmann, Stuttgart)
Seitenanfang Seite drucken